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Prognostic Value of Mid-Regional Pro-
Adrenomedullin Levels Taken on Admission and
Discharge in Non–ST-Elevation Myocardial Infarction
The LAMP (Leicester Acute Myocardial Infarction Peptide) II Study
Onkar S. Dhillon, BSC, MBCHB,* Sohail Q. Khan, BSC (HONS), MBCHB, MD,*
Hafid K. Narayan, MBCHB,* Kelvin H. Ng, MBCHB,* Joachim Struck, PHD,†
Paulene A. Quinn, MPHIL,* Nils G. Morgenthaler, MD,† Iain B. Squire, MD,*
Joan E. Davies, PHD,* Andreas Bergmann, PHD,† Leong L. Ng, MD*
Leicester, United Kingdom; and Hennigsdorf, Germany
Objectives The purpose of this study was to assess the prognostic value of admission and discharge mid-regional pro-
adrenomedullin (sAM) levels in non–ST-elevation myocardial infarction (MI) and identify values to aid clinical de-
cision making. N-terminal pro–B-type natriuretic peptide and GRACE (Global Registry of Acute Coronary Events)
score were used as comparators.
Background sAM is a stable precursor of adrenomedullin.
Methods We measured plasma sAM on admission and discharge in 745 non–ST-elevation MI patients (514 men, median
age 70.0  12.7 years). The primary end point was a composite of death, heart failure, hospitalization, and re-
current acute MI over mean follow-up of 760 days (range 150 to 2,837 days), with each event assessed individu-
ally as secondary end points.
Results During follow-up, 120 (16.1%) patients died, and there were 65 (8.7%) hospitalizations for heart failure and
77 (10.3%) recurrent acute MIs. Both admission and discharge levels were increased (median 0.81 nmol/l
[range 0.06 to 5.75 nmol/l] and 0.76 nmol/l [range 0.25 to 6.95 nmol/l], respectively) compared with estab-
lished normal ranges. Multivariate adjusted Cox regression models revealed that both were associated with the
primary end point (hazard ratio: 9.75 on admission and 7.54 on discharge; both p  0.001). Admission sAM
was particularly associated with early (30 days) mortality (c-statistic  0.90, p  0.001), and when compared
with N-terminal pro–B-type natriuretic peptide and GRACE score, it was the only independent predictor of this
end point. Admission sAM 1.11 nmol/l identified those at highest risk of death (p  0.001). Patients with
above-median admission sAM may benefit from revascularization.
Conclusions sAM level is prognostic for death or heart failure. Admission levels are a strong predictor of early mortality and,
when 1.11 nmol/l, complements the GRACE score to improve risk stratification. (J Am Coll Cardiol 2010;56:
125–33) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.01.060t
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ow has a higher annual prevalence than ST-segment elevation
yocardial infarction (STEMI) (1), and although in-hospital
ortality rates are lower, they gradually increase and in the
ong term are higher than in STEMI patients (2). In this
eterogeneous disorder, identifying where an individual lies on
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ent (3). For example, risk stratification may be useful when
alancing the risk and potential benefit of invasive treatment in
n aging population. Promising risk stratification tools and
iomarkers have emerged such as the GRACE (Global Reg-
stry of Acute Coronary Events) score (4) and N-terminal
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(NT-proBNP) (5), but neither is
fully discriminatory. A multima-
rker strategy may become the most
effective tool for risk prediction
(6), and new markers should offer
new information over available
clinical and biochemical factors.
Adrenomedullin (AM) is a
52-amino-acid peptide that is el-
evated in heart failure (HF) (7)
and post–acute coronary syn-
drome (ACS) (8). Discovered in
human phaechromocytoma, it is
also present in heart, brain, lung,
kidney, and gastrointestinal or-
gans and elicits its potent vaso-
dilatory activity (9) through an
increase in cyclic adenosine mono-
phosphate levels. AM increases
cardiac output and induces a di-
uresis and natriuresis (10), and
the elevated levels found in HF
and myocardial infarction (MI)
are also predictive of adverse
events (11). Despite this clear
role in cardiovascular homeosta-
sis and pathogenesis, further in-
vestigation of plasma AM levels
is hampered by its short half-life
(22 min), rapid clearance, and
the presence of a binding protein
(12). AM is derived from a larger
(185 amino acid) precursor mol-
cule (13). A more stable mid-regional fragment composed
f amino acids 45 to 92 of pre-pro-AM has been identified,
hich is secreted in equimolar amounts (12), and therefore
cts as a surrogate for adrenomedullin (sAM) levels. Our
enter (14) previously showed that this mid-regional frag-
ent has independent prognostic value but in a cohort of
rimarily STEMI patients with levels measured solely on
ischarge. In this study, we addressed the use of mid-
egional pro-AM (sAM) in NSTEMI and compared the
rognostic value of admission and pre-discharge levels for
ajor adverse cardiac events (MACE) using NT-proBNP
nd the GRACE score as benchmark comparators. Further-
ore, we identified a cutoff level that could aid clinical
ecision making.
ethods
tudy population. We studied 745 NSTEMI patients
dmitted to University Hospitals of Leicester NHS trust
nd primarily recruited between August 2005 and April
007. Attempts were made to enroll all consecutive
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
AM  adrenomedullin
AMI  acute myocardial
infarction
BNP  B-type natriuretic
peptide
eGFR  estimated
glomerular filtration rate
HF  heart failure
HR  hazard ratio
MACE  major adverse
cardiac event(s)
MI  myocardial infarction
NRI  net reclassification
improvement
NSTEMI  non–ST-segment
elevation myocardial
infarction
NT-proBNP  N-terminal
pro–B-type natriuretic
peptide
ROC  receiver-operator
characteristic
sAM  mid-regional pro-
adrenomedullin abbreviated
to surrogate for
adrenomedullin
STEMI  ST-segment
elevation myocardial
infarctionSTEMI patients, but approximately 20 to 40 declined. phe study complied with the Declaration of Helsinki and
as approved by the local ethics committee; written in-
ormed consent was obtained from all patients. AMI was
iagnosed if a patient had a cardiac troponin I level above
he 99th centile for our population with at least one of the
ollowing: chest pain lasting 20 min or diagnostic serial
lectrocardiographic changes consisting of new pathological
waves or ST-segment and T-wave changes (15). Exclu-
ion criteria were known malignancy, renal replacement
herapy, or surgery in the previous month. Demographic,
linical, biochemical, and echocardiographic data were ob-
ained. The estimated glomerular filtration rate (eGFR) was
alculated from the simplified formula derived from the
odification of Diet in Renal Disease study (16). All
atients received standard medical treatment, and revascu-
arization was at the discretion of the attending physician.
lasma samples. Blood samples were drawn after 15 min
f bed rest into tubes containing ethylenediamine tetraacetic
cid and aprotinin. Admission levels refer to those obtained
fter diagnosis of NSTEMI but within 36 h of onset of
ymptoms, and discharge levels were taken 3 to 5 days
ost-admission. Plasma was stored at 80°C until assayed
n a single batch for determination of plasma sAM and
T-proBNP with both clinicians and patients blinded to
he results.
chocardiography. Transthoracic echocardiography was
erformed in 501 (67.2%) patients during the index admis-
ion but after day 3 using either a Sonos 5500 or IE 33
nstrument (Philips Medical Systems, Reigate, United
ingdom). A 16-segment left ventricular wall motion index
core was determined based on the American Society of
chocardiography method. In suitable patients, the left ven-
ricular ejection fraction was calculated using the biplane
ethod of disks formula. Impaired left ventricular systolic
unction was defined as either a left ventricular ejection fraction
40% or a ventricular wall motion index score 1.8.
RACE scoring. Based on an international observational
atabase of ACS patients, GRACE scores can be calculated
n initial presentation to primarily predict in-hospital mor-
ality and reinfarction rates (4). When calculated before
ischarge, it includes age, heart rate, systolic blood pressure,
erum creatinine, congestive heart failure, ST-segment de-
ression, increased cardiac enzymes, history of MI or
oronary artery bypass graft, and whether in-hospital revas-
ularization was performed, and it shows superior estima-
ion of 6-month mortality and reinfarction rates. We
alculated both scores, but only used scores on initial
resentation for comparison with events at 30 days.
T-proBNP assay. Our NT-proBNP assay was based on
noncompetitive assay, as previously published (5). The
ower limit of detection was 0.3 pmol/l. Pre-discharge levels
f NT-proBNP were used unless otherwise specified.
AM assay. sAM was detected using a novel commercial
ssay (BRAHMS AG, Hennigsdorf, Germany), as previ-
usly described (17). Briefly, tubes were coated with a
urified sheep polyclonal antibody raised against a peptide
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July 6, 2010:125–33 The LAMP II Studyepresenting amino acids 83 to 94 of pre-pro-AM. A purified
heep methylacridinium N-hydroxysuccinimide ester–labeled
olyclonal antibody directed against amino acids 68 to 86 of
re-pro-AM was used as a tracer. The immunoassay was
erformed by incubating 10 l of samples/standards and 200
l of tracer in coated tubes for 2 h at room temperature and
easuring the bound chemiluminescence using an LB952T
uminometer (Berthold, Bad Wildbad, Germany). The lower
etection limit of the assay is 0.08 nmol/l. The intra-assay
interassay) coefficients of variation at 0.5 and 5 nmol/l were
% (8.5%) and 3.5% (6.5%), respectively.
nd points. The primary composite end point was
ACE, including all-cause mortality, HF hospitalization,
r recurrent AMI, all evaluated individually as secondary
nd points within 30 days, 6 months, and 2 years. This
ontrasts with the previous study (14) from our center that
eported death or readmission with HF as the primary
utcome measure because NT-proBNP, not GRACE
core, was used as the primary comparator and has a
ecognized association with death and HF readmission (14).
owever, GRACE score estimates the risk of death or
ecurrent MI (4) and to enable nonbiased comparison with
his marker as well, readmission with AMI was added to the
rimary end point. Hospitalization for HF was defined as a
ospital readmission for which HF was the primary reason,
equiring treatment with high-dose diuretics, inotropes, or
ntravenous nitrate. Recurrent AMI could occur on index
dmission or on rehospitalization and was diagnosed if the
ardiac troponin I level was above the 99th centile for our
opulation with at least 1 of the following: chest pain lasting
20 min or diagnostic serial electrocardiographic changes
onsisting of new pathological Q waves or ST-segment and
-wave changes (15). End points were obtained by review-
ng the local hospital databases and the Office of National
tatistics Registry and by phone calls to patients. We
chieved 100% follow-up.
tatistical analysis. Statistical analyses were performed
sing SPSS version 14 (SPSS Inc., Chicago, Illinois).
ssuming an event rate of 15% and that the covariates
redict up to 30% of the variance of the biomarker, a sample
ize of 600 patients would be powered (89.6% at p  0.05)
o detect a hazard ratio (HR) of the biomarker of 1.5. We
ecruited 600 patients to cover for loss to follow-up. sAM
nd NT-proBNP levels were log10-transformed, and there-
ore, HRs refer to a 10-fold increase in the levels of these
arkers. GRACE scores were used as the original scores.
onparametric tests were used against non-Gaussian data
Mann-Whitney U test, Kruskal-Wallis test, and Spearman
rs] correlations). Correction for multiple comparisons was
one with Hochberg’s GT2 test, and all significance levels
uoted are 2 tailed. Independent predictors of sAM levels
ere assessed using univariate general linear models. To
ssess the prognostic value of the peptides, 2 multivariate
ox regression models were constructed. First, a base model
as generated that included variables that were significantly
p  0.20) associated with any of the study end points on dnivariate analysis (age, sex, history of angina, AMI, hyper-
ension or diabetes, Killip class, eGFR, log glucose level,
nd log troponin I [with addition of echocardiographic data
n a separate model]). Either admission sAM or discharge
AM levels were added to this model to evaluate the relative
rognostic value of each with all variables entered simulta-
eously. A second comparative Cox model was used to
ssess the relative prognostic power of sAM, NT-proBNP,
nd GRACE score. This model excluded age and eGFR
ecause both are included in calculating GRACE scores.
eceiver-operator characteristic (ROC) curves with c-statistics
ere calculated. Kaplan-Meier survival analysis and Mantel-
ox log-rank tests were performed. The additional prognostic
alue of sAM taken at admission or discharge to the GRACE
core was evaluated by reclassification analysis with calculation
f net reclassification improvement (NRI) as described by
encina et al. (18).
We sought interactions between the plasma levels of
AM and revascularization in Cox models to investigate the
sefulness of this biomarker in directing intervention. As
hese were observational data, models were corrected for the
robability of receiving revascularization (the propensity
core, which was calculated as the probability of revascular-
zation using the following predictive variables: age, sex,
istory of MI, angina, hypertension, diabetes, Killip class,
GFR, site of MI, drug therapies).
esults
atient characteristics. The characteristics of the study
opulation are shown in Table 1, of which 109 (14.6%) were
rom the Indian subcontinent. Of the 745 patients, 631 had
AM levels taken within 36 h of symptoms, 684 had levels
btained before discharge, and 700 had NT-proBNP levels.
uring a follow-up of a mean of 760 days (range 150 to
,059 days), 120 (16.1%) patients died, 65 (8.7%) were
eadmitted with HF, and 77 (10.3%) had a reinfarction.
AM levels in NSTEMI patients. Both admission and
ischarge sAM levels were increased (median levels of 0.81
mol/l [range 0.06 to 5.75 nmol/l] and 0.76 nmol/l [range
.25 to 6.95 nmol/l], respectively) compared with a disease-
ree cohort (721 people of whom 417 were male, mean age
1.6 years; median 0.47 nmol/l, range 0.27 to 1.18 nmol/l).
ndependent predictors of admission sAM showed the
ollowing significant predictors: age, eGFR, history of
iabetes, Killip class 1, and loop diuretic therapy (all p 
.001). Independent predictors of discharge sAM included
ge, eGFR, Killip class 1 (all p  0.001), loop diuretic
herapy (p  0.026), and history of MI (p  0.02).
eta-blockers were not a significant predictor of sAM
evels.
sAM levels were also higher in those who reached the
rimary end point compared with the event-free survivors
admission sAM 1.11 nmol/l [range 0.06 to 5.75 nmol/l] vs.
.72 nmol/l [range 0.09 to 2.75 nmol/l], p  0.001;
ischarge sAM 1.09 nmol/l [range 0.33 to 6.95 nmol/l] vs.
0
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Fig. 1). Both showed a comparable relationship to clinical
nd other variables (Table 2).
T-proBNP levels in NSTEMI patients. NT-proBNP
evels ranged from 0.12 to 24,016 pmol/l, with a mean of
,318 pmol/l, and showed a typical distribution across
ariables (Table 2).
rognostic value of early versus pre-discharge sAM
evels. For the primary end point, multivariate Cox analysis
howed that admission sAM levels were predictive of
ACE (HR: 9.75, p  0.001) along with age and, in the
ubset of patients with echocardiographic data, impaired left
entricular function (HR: 1.95, p 0.001). Discharge sAM
as also predictive (HR: 7.54, p  0.001) along with age
nd Killip class 1 (HR: 1.49, p  0.021).
Examination of the relationship with the secondary
nd points revealed a difference between the prognostic
alue of sAM taken at the 2 time points (Table 3). High
haracteristics of the 745 NSTEMI Patients According to sAM LevTable 1 Characteristics of the 745 NSTEMI Patients According
Demographics All (N  745)
1
<0.653 (n 
Age, yrs 70.0 12.7 59.0 10.
Male sex 514 (69.0) 169 (80.5
Previous cardiovascular disease
Myocardial infarction 209 (28.1) 45 (21.4
Angina pectoris 243 (32.6) 32 (15.2
Heart failure 17 (2.3) 3 (1.4)
Cardiovascular risk factors
Hypertension 428 (57.4) 97 (46.3
Diabetes mellitus 199 (36.7) 31 (14.8
Hypercholesterolemia 281 (37.7) 95 (45.2
Current/ex-smoker 439 (58.9) 131 (62.4
Risk markers on admission
Killip class 1 268 (36.0) 30 (14.3
Glucose, mmol/l (n  599)* 7.1 4.0 6.4 3.0
Troponin I (NR 0.06) 1.92 7.46 1.49 6.2
eGFR (ml/min/1.73 m2 SA) 63.6 20.6 73.8 15.
Risk markers on discharge
Ejection fraction (n  382)* 45.0 17.2 55.0 18.
GRACE score (n  623)* 121 34.8 97.5 28.
NT-proBNP, pmol/l (n  700)* 567.4 1,983.6 183.4 692
Medications on discharge
Aspirin 613 (82.3) 184 (87.6
Beta-blocker 556 (74.6) 177 (84.3
ACE inhibitor or ARB 520 (69.8) 162 (77.1
Statin 582 (78.1) 194 (92.4
Revascularization within 30 days 148 (23.5) 65 (30.9
Major cardiac event rate at 1 yr
Death 82 (11.0) 3 (1.4)
Heart failure 56 (7.5) 6 (2.9)
Re-AMI 61 (8.2) 11 (5.2)
alues shown are n (%) or median  SD. *Number of patients with data available on that variabl
ACE  angiotensin-converting enzyme; ARB  angiotensin II receptor blocker; eGFR  estima
T-proBNP N-terminal pro–B-type natriuretic peptide; Re-AMI recurrent acute myocardial infarc
nfarction.arly levels of sAM have a stronger relationship with seath than pre-discharge levels (HR: 16.68 vs. 7.70; both
 0.001). Using Kaplan-Meier analysis, Figure 2 shows
hat when the cohort is separated into 3 groups by
dmission sAM level, it allowed identification of patients
t low, medium, and high risk of death (log-rank test:
5.44, p  0.001). There is early separation of the survival
lot; this represents no deaths in patients in the lowest
ertile by 30 days, 1 in the second, and 19 in the highest.
ultivariate Cox analysis for death at 30 days revealed that
1-SD increase in log-transformed admission sAM was
ssociated with a 117-fold increase in hazard (95% confi-
ence interval [CI]: 8.35 to 1,636.18, p  0.001) compared
ith discharge sAM (HR: 27.89, 95% CI: 3.77 to 206.53,
 0.001). Admission sAM was associated with HF
eadmission (HR: 8.39, p  0.018) along with Killip class
1 (HR: 2.77, p  0.003) and impaired left ventricular
unction (HR: 2.00, p  0.028), but this was weaker than
or discharge sAM (HR: 15.99, p  0.001). This leads to a
n AdmissionAM Levels on Admission
Admission sAM Tertiles, nmol/l
p Value
2 3
0.653-1.020 (n  210) >1.020 (n  211)
69.0 11.7 79.0 9.2 0.001
145 (69.0) 124 (58.8) 0.001
60 (28.6) 98 (46.4) 0.001
66 (31.4) 73 (34.6) 0.001
1 (0.5) 10 (4.7) 0.008
133 (63.3) 146 (69.2) 0.001
63 (30.0) 84 (39.8) 0.001
82 (39.0) 82 (38.9) 0.319
123 (58.6) 110 (52.1) 0.100
73 (34.8) 128 (60.7) 0.001
7.1 3.5 8.4 5.3 0.001
1.81 7.66 3.01 8.30 0.006
63.5 17.0 46.5 17.7 0.001
51.5 16.3 37.0 17.7 0.001
120.5 28.2 155.0 26.7 0.001
481 1,089.2 2,216.9 2,052.0 0.001
175 (83.3) 147 (69.7) 0.001
161 (76.7) 136 (64.5) 0.001
171 (81.4) 147 (69.7) 0.017
182 (86.7) 154 (73.0) 0.001
60 (28.6) 23 (10.9) 0.001
14 (6.7) 54 (25.6) 0.001
14 (6.7) 29 (13.7) 0.001
20 (9.5) 25 (11.8) 0.055
merular filtration rate; GRACE  Global Registry of Acute Coronary Events; NR  normal range;
 surface area; sAM surrogate for adrenomedullin, STEMI ST-segment elevation myocardialels oto s
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July 6, 2010:125–33 The LAMP II Studynd point overall. No association with recurrent MI was
bserved.
The difference in levels between the 2 sampling times was
lso evaluated, which revealed a univariate association with
Figure 1
Admission sAM Levels Compared Between
NSTEMI Patients Who Did and Did Not Reach
the Primary End Point and Normal Controls
Box and whisker plot. Central line  median level, box  interquartile range,
whiskers  5th and 95th centiles, dotted line  optimum cut off to identify
high-risk patients of 1.11 nmol/l. A-sAM  surrogate for adrenomedullin at
admission; NSTEMI  non–ST-segment elevation myocardial infarction.
AM Levels Taken on Admission and Discharge and NT-ProBNP LevTable 2 sAM Levels Taken on Admission and Discharge and NT
Admission sAM, nmol/l (n  631)
Median* p Value
Male (n  514)† vs. female 0.74 0.95 0.001
History of
AMI (n  209) vs. no AMI* 1.01 0.75 0.001
Angina (n  243) 1.00 0.73 0.001
Diabetes (n  199) 0.96 0.74 0.001
Hypertension (n  428) 0.89 0.69 0.001
Clinical factors
Killip class 1 (n  268) 1.11 0.68 0.001
Echocardiography (n  509)
Impaired left ventricular function
(n  226)
0.93 0.72 0.001
Major cardiac event
Death (n 120) 1.34 0.72 0.001
Heart failure ( n  65) 1.13 0.72 0.001
Re-AMI (n  77) 0.90 0.72 0.002
Correlations rs p Value
Age 0.567 0.001
eGFR 0.640 0.001
Log glucose (n  599)‡ 0.289 0.001
Ejection fraction 0.273 0.001
Log troponin 0.144 0.001
Discharge GRACE score (n  623)‡ 0.619 0.001
NT-proBNP (n  700)‡ 0.656 0.001
Notemedian values are all presented in the same order with the value for patients with the variable
ith that variable present. ‡Number of patients with data available on that variable if 745.
AMI  acute myocardial infarction; Re-AMI  recurrent acute myocardial infarction; other abbreviationeath (HR: 2.48, p  0.002) but no other end points. This
elationship was lost on multivariate analysis.
omparison of prognostic value of admission sAM,
RACE score, and NT-proBNP. PRIMARY COMPOSITE
ND POINT: MACE. Using the comparative Cox regression
odel, all 3 markers were significant independent predictors
f the primary end point: NT-proBNP (HR: 1.54, 95% CI:
.07 to 2.24, p  0.027), GRACE score (HR: 1.01, 95%
I: 1.01 to 1.02, p  0.001), and admission sAM (HR:
.44, 95% CI: 1.25 to 9.50, p  0.017). Results are shown
or the model containing admission sAM but were similar
or discharge sAM. ROC curve c-statistics illustrate that
verall discriminatory ability for the primary end point is
imilar among prognostic markers for admission sAM (HR:
.72, 95% CI: 0.67 to 0.77), NT-proBNP (HR: 0.73, 95%
I: 0.69 to 0.77), and GRACE score (HR: 0.71, 95% CI:
.66 to 0.76), all at p  0.001.
ECONDARY END POINTS. Table 4 shows the relationship
etween admission sAM, NT-proBNP, and GRACE score
nd mortality in the long (mean 760 days), medium
6 months), and short term (30 days) by Cox regression
nalysis. For long-term mortality, NT-proBNP was dis-
laced by admission sAM and GRACE score with no
ther significant covariates. The GRACE score c-statistic
f 0.80 (95% CI: 0.73 to 0.86) could be improved to 0.84
cross Different Patient GroupsNP Levels Across Different Patient Groups
Discharge sAM, nmol/l (n  684) NT-proBNP, pmol/l (n  700)
Median* p Value Median* p Value
0.71 0.87 0.001 508 1,006 0.002
1.02 0.71 0.001 1,131 461 0.001
0.86 0.71 0.001 837 483 0.001
0.70 0.90 0.001 1,002 466 0.001
0.82 0.64 0.001 759 378 0.001
1.04 0.66 0.001 1,597 357 0.001
0.83 0.68 0.001 1,116 322 0.001
1.21 0.71 0.001 2,316 383 0.001
1.11 0.71 0.001 1,936 383 0.001
0.83 0.71 0.002 854 383 0.001
rs p Value rs p Value
0.614 0.001 0.534 0.001
0.648 0.001 0.490 0.001
0.292 0.001 0.233 0.001
0.219 0.001 0.440 0.001
0.075 0.075 0.169 0.001
0.630 0.001 0.557 0.001
0.644 0.001 — —
stion present in the first column and those with variable absent in the second. †Number of patientsels A-ProB
in ques as in Table 1.
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The LAMP II Study July 6, 2010:125–3395% CI: 0.78 to 0.90) when combined with admission
AM (c-statistic 0.82, 95% CI: 0.77 to 0.88), all p  0.001.
dmission sAM is a stronger predictor of mortality at 6
onths than the GRACE score in this cohort (HR: 2.45, p
.002 and HR: 1.01, p  0.045, respectively), and it was the
nly marker to retain independent prediction of death at 30
ays (HR: 66.89, p 0.004; c-statistic: 0.90 [95% CI: 0.85 to
.95], p  0.001) (even when both the GRACE scores on
dmission and pre-discharge were assessed).
ECLASSIFICATION ANALYSIS. To evaluate the additional
ontribution of admission sAM levels to the GRACE score
calculated on presentation) for prediction of early mortality
t 30 days, we performed reclassification analysis (18) with
alculation of NRI by the following method. Individuals
ere classified into risk tertiles using binary logistic regres-
ion with the GRACE score as the covariate and then
eclassified with admission sAM as a further covariate in the
egression model. The change in risk tertiles for the end
ox Regression Analysis and Receiver-Operator Characteristic Curvor Admission and Discharge sAM Levels Across Primary and SeconTable 3 Cox Regressio Analysis and Receiver-Operator Characfor Admission and Discharge sAM Levels Across Prima
End Point
Admission sAM
HR (95% CI)* p Value
c-Sta
(95%
MACE 9.75 (3.36–26.16) 0.001 0.72 (0.
Death 16.68 (4.56–60.99) 0.001 0.79 (0.
Heart failure 8.39 (1.44–48.96) 0.018 0.70 (0.
Re-AMI 1.70 (0.26–7.36) 0.512 —
After adjustment for the following variables: age, sex, history of angina, AMI, hypertension or dia
separate model.
CI  confidence interval; HR  hazard ratio; MACE  major adverse cardiac event; other abbre
Figure 2 Cumulative Probability of Death
According to Tertile of sAM Level on Admission
The first 40 days are magnified in the inset. There were 120 deaths in the
study cohort. Log-rank test: 75.44, p  0.001. sAM  mid-regional
pro-adrenomedullin abbreviated to surrogate for adrenomedullin.ioint of mortality at 1 month is shown in Table 5.
dmission sAM improved the classification in 168 subjects
ho did not experience the end point and made it worse in
6, while improving classification in 2 subjects who experi-
nced the end point, resulting in a significant NRI of 34.1%
range 18.6% to 49.5%), p  0.00001 (discharge sAM
emonstrated an NRI of 23.1% [range 3.6% to 42.6%], p 
.002). For prediction of early mortality, prognostic markers
hat can be performed on admission are advantageous;
herefore, for the purpose of comparison, we assessed the
dditional contribution of admission levels of NT-proBNP
o the GRACE score. Admission NT-proBNP level failed
o significantly improve the overall classification of individ-
als into risk tertiles with a calculated NRI of 1.1% (range
18.9% to 21.1%), p  0.917.
Significant independent predictors of HF were Killip
lass 1 (HR: 2.49; 95% CI: 1.29 to 4.80, p  0.006) and
T-proBNP (HR: 2.02, 95% CI: 1.05 to 3.88, p  0.036)
ut not admission sAM (p  0.215) or impaired left
entricular function (p  0.074). However, discharge sAM
evel is a strong predictor of this outcome (HR: 10.11, 95%
I: 2.36 to 43.31, p  0.002) that displaces NT-proBNP
p  0.072) when substituted into the model, with Killip
lass remaining significant (HR: 2.60, p  0.004). ROC
urve analysis showed a c-statistic of 0.74 for both NT-
roBNP and discharge sAM, which increased to 0.76 with
oth markers combined. Because the GRACE score is not
esigned to predict readmission with HF, it was not
valuated against this end point. Neither biomarkers nor the
RACE score predicted recurrent MI as an individual end
oint in multivariate analysis.
omplementary use of admission sAM and GRACE
core. We assessed whether the strong association of ad-
ission sAM with mortality could be used to improve risk
tratification by the GRACE score. ROC analyses provided
he optimum cutoff value for admission sAM for prediction
f death at 1.11 nmol/l (67% sensitivity, 22% false-positive
ate) and predicted optimum survival stratification on
aplan-Meier analysis (log-rank test: 85.19, p 0.001). Of
he 16 patients who died by day 30, 15 (94%) had levels
bove this value. A total of 564 patients had both GRACE
core and admission sAM data. This cohort was separated
tatisticEnd Pointstic Curve c-Statistic
d Secondary End Points
Discharge sAM
HR (95% CI)* p Value
c-Statistic
(95% CI)
7) 7.54 (3.30–17.25) 0.001 0.73 (0.69–0.77)
4) 7.70 (2.53–23.44) 0.001 0.76 (0.71–0.81)
7) 15.99 (4.18–61.12) 0.001 0.74 (0.68–0.80)
1.38 (0.26–7.36) 0.708 —
Killip class, eGFR, log glucose level, and log troponin I with addition of echocardiographic data in
as in Tables 1 and 2.e c-Sdaryteris
ry an
tistic
CI)
67–0.7
74–0.8
63–0.7
betes,nto centiles by the GRACE score to avoid loss of prog-
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July 6, 2010:125–33 The LAMP II Studyostic value due to oversimplification. The improvement in
isk stratification using knowledge of sAM levels was most
vident in the top 5 centiles of the GRACE score (log-rank
est: 15.71, p  0.001 pooled comparison) (Fig. 3). For
xample, for those with GRACE scores in the top centile,
n admission sAM level of 1.11 nmol/l identified those
ith 46.5% mortality rate during the follow-up period and,
f 1.11 nmol/l, isolated those with a risk comparable to
aving a GRACE score in the 6th centile in this cohort
15.4% vs. 16.1%).
nteraction of admission sAM levels and revascularization.
he data show that the revascularization by day 30 (Table 1)
ates were reduced in high-risk patients at 10.9% in pa-
ients with admission sAM levels in the top tertile compared
ith 28.6% and 30.9%, respectively, for the middle and
owest tertiles of admission sAM (confirming the risk-
verse management that is prevalent in many other regis-
ries). A propensity score for predicting revascularization
as calculated from variables listed in the statistical analysis
ection. ROC curve analysis of the propensity score for
rediction of actual revascularization showed reasonable
iscrimination (c-statistic: 0.71, p  0.0005). Cox models
or the prediction of MACE incorporating factors in the
ase model, with the addition of revascularization, admis-
ion sAM, and an interaction term (revascularization 
dmission sAM) and the propensity score for revasculariza-
ion, yielded the following HR for significant predictors:
dmission sAM: 3.69 (p  0.02). The interaction term
evascularization*admission sAM was significant (p 
.02). Kaplan-Meier plots of the effect of revascularization
n MACE of patients stratified by the admission sAM
ultivariate Cox Regression Analyses Comparing Admission sAM,nd NT-proBNP for Prediction of Death at 1 Mo th, 6 Months, andTable 4 Multivariate C x Regres ion An lyses Compari g dmand NT-proBNP for Prediction of Death at 1 Month, 6 M
Death (Mean 760 Days)
HR (95% CI) p Value H
Admission sAM 15.79 (3.64–68.59) 0.001 22.4
GRACE score 1.01 (1.004–1.03) 0.005 1.0
NT-proBNP — 0.355
bbreviations as in Tables 1 and 3.
mprovement in Identification of Event-Free Patients and Those Whsing Admiss on sAM Levels in Addition to GRACE Score Tertiles UTable 5 Improvement in Identification of Event-Free Patients anUsing Admission sAM Levels in Addition to GRACE Sco
GRACE  Admission sAM
GRACE Score Low (n) Intermediate (n) High (n) In
Event-free at 30 days (n  561)
Low 174 16 1
Intermediate 101 69 19
High 18 49 114
Event by day 30 (n  19)
Low 0 1 0
Intermediate 0 1 1
High 0 0 16
NRI, %RI  net reclassification improvement; other abbreviations as in Table 1.edian level are presented in Figure 4. Revascularization
as associated with reduced MACE in patients whose
dmission sAM levels were above the median (p 0.05) but
ot significantly in those with admission sAM below the
edian.
iscussion
dvancing from a previous study from our center (14) that
dentified the prognostic value of sAM in a primarily
TEMI population, this is the first report demonstrating
he biomarker’s substantial prognostic value in a large cohort
f patients with NSTEMI, and it also addresses the
ptimum time to measure sAM. Levels taken within 36 h of
ymptoms displayed similar overall prediction for MACE as
hose taken before discharge but with an important caveat;
dmission levels are strongly associated with increased risk
f death, particularly early mortality, where they are superior
o NT-proBNP and the GRACE score, whereas pre-
ischarge levels demonstrate a stronger association with HF
eadmission that is comparable to NT-proBNP.
Because AM has shown numerous cardioprotective ef-
ects (19,20), it is initially counterintuitive that high levels
re associated with adverse events. It has been argued that
M counterbalances other negative processes, which is
upported by studies showing AM infusions enhancing left
entricular function (20) with similar beneficial actions seen
n patients with HF (21). This paradox mirrors that already
een with B-type natriuretic peptide (BNP) as does the
ariation in sAM levels across clinical factors, such as age
nd sex. Furthermore, a significant correlation between the
E Score,nded Follow-UpsAM, GRACE Score,
s, and Extended Follow-Up
eath at 6 Months Death at 1 Month
% CI) p Value HR (95% CI) p Value
2–161.6) 0.002 66.89 (3.92–1,141.7) 0.006
0–1.03) 0.045 — 0.761
0.390 — 0.530
d by Day 30Reclassification Analysisose Who Died by Day 30
rtiles Using Reclassification Analysis
Reclassification
Net
Improvement (n)
% Correctly
Reclassified p Valueed (n) Decreased (n)
168 132 132/561  23.53
0 2 2/19 10.53
34.06 0.00001GRACExteissio
onth
D
R (95
5 (3.1
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The LAMP II Study July 6, 2010:125–33iomarkers (8,14) was found, with them sharing 43% of the
ame information, and overall one could extrapolate that
elease of AM and BNP may share the same stimuli.
onsequently, multicollinearity may explain why NT-
Figure 3
3-Dimensional Bar Chart of Mortality
Rates in Top 5 GRACE Score Centiles
Before and After Restratification by sAM Levels
This bar chart shows the mortality rate in the study population with GRACE
(Global Registry of Acute Coronary Events) scores in the top 5 centiles (1 to 10
lowest to highest scores) further divided by admission sAM level (low is 1.11
nmol/l [green columns], high is 1.11 nmol/l [purple columns]). This shows
that sAM further improves risk stratification particularly helping to identify the
highest risk patients. Abbreviation as in Figure 1.
Figure 4 Cumulative MACE (%) of Patients Stratified by Median A
Using the propensity score method for predicting revascularization, Kaplan-Meier h
admission sAM level who undergo revascularization before 30 days had a major a
larization (A), whereas patients with a high (above the median) admission sAM lev
Abbreviation as in Figure 1.roBNP is displaced from Cox analysis by sAM for both
eath and HF readmission.
AM has pleiotropic effects both against the arterial
esponse to injury (22) and on left ventricular remodeling
20). An unstable atheromatous plaque underpins the eti-
logy of an ACS, and one could speculate that the link
etween higher initial levels and mortality may reflect a
reater burden of deleterious arterial processes that are being
ounterbalanced by increased AM production. Levels at
ischarge showed a stronger relationship with HF readmis-
ion because they are likely to relate to the remodeling
rocess that is under way at that time. The potent associa-
ion with adverse events clearly illustrates the significance of
M as an independent neurohormonal pathway and, in
iew of its beneficial effects, a potential therapeutic pathway.
AM levels peak 24 to 48 h after onset (8), and the
mportance of timing of blood sampling for prognostication
s illustrated by previous studies in STEMI patients treated
y primary percutaneous coronary intervention (23). Katay-
ma et al. (23) concurred with our current findings by also
emonstrating AM as a stronger prognostic marker of early
ortality than NT-proBNP when levels were measured
4 h after onset.
International guidelines (3) recognize that risk stratifica-
ion plays a central role in the optimum management of
on–ST-segment elevation ACS, which has been com-
ounded by the results of recent studies. For example,
ehta et al. (24) did not find early intervention beneficial
ompared with a delayed approach unless patients had
RACE scores in the top tertile. The present study
emonstrates that using a simple cutoff value of sAM of
.11 nmol/l can markedly improve risk stratification over
RACE scoring alone.
sion sAM Levels and Effect of Revascularization Within 30 Days
plots were constructed. These suggest that patients with a low (below median)
cardiac event (MACE) rate similar to that of those who do not undergo revascu-
e a reduced MACE rate if they undergo revascularization within 30 days (B).dmis
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July 6, 2010:125–33 The LAMP II StudyWe also examined the effect of revascularization within
0 days on outcomes, after stratification by sAM levels and
djusting Cox models for propensity scores of likelihood of
evascularization. These preliminary data suggest that the
dmission sAM level may help to identify patients who will
enefit most from revascularization. The use of sAM to
elect patients for invasive or potentially hazardous treat-
ents may be a step toward a personalized management
pproach, but further prospective, randomized studies are
eeded to confirm this.
tudy limitations. Our findings were based on a single-
enter population, with 2 admitting hospitals, and would
eed to be verified in other populations. The rate of early
evascularization in our NSTEMI population was low,
3.5% by day 30, and may not reflect a more contemporary
nvasive approach of revascularization within 72 h of pre-
entation. Correction of hazard models using propensity
cores for revascularization may not completely remove bias
rom unmeasured factors.
onclusions
his is the first report confirming activation of the AM system
n a cohort of patients with NSTEMI. sAM is a stable
recursor released in equimolar amounts that represents a
owerful new biomarker of risk of adverse events, death, or HR
ehospitalization beyond established clinical, biochemical, or
chocardiographic markers, NT-proBNP, and GRACE score.
dmission sAM level is a particularly strong predictor of early
ortality and, when 1.11 nmol/l, complemented the
RACE score to improve risk stratification.
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